PRQR
ProQR Therapeutics BV
1.60$
-3.7%
vs. previous close
Closing price · As of: Oct 8, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | 15.6% | 11.3% | – | – | – | – | – | 14.5% | 34.1% | 8.1% | – | |
| 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 85.5% | 65.9% | 91.9% | 88.7% | |
| 397.5% | 235.5% | 208.6% | 111.8% | 245.0% | 246.4% | 272.7% | 298.9% | 380.1% | 211.6% | 581.9% | 144.6% | 247.2% | |
| 242.0% | 144.6% | 77.6% | 47.8% | 85.4% | 90.9% | 71.6% | 126.2% | 107.0% | 83.8% | 186.4% | 55.2% | 85.1% | |
| 639.5% | 290.9% | 281.5% | 157.1% | 326.8% | 334.1% | 339.3% | 420.9% | 487.1% | 280.2% | 737.2% | 192.6% | 321.6% | |
| -539.5% | -190.9% | -181.5% | -57.1% | -226.8% | -234.1% | -239.3% | -320.9% | -387.1% | -194.6% | -671.4% | -100.7% | -233.0% | |
| 0.8% | 8.4% | 0.1% | 0.0% | – | – | – | – | – | – | – | – | – | |
| -392.6% | -166.8% | -172.0% | -45.9% | -211.0% | -216.0% | -223.0% | -318.6% | -377.6% | -190.3% | -658.3% | -99.4% | -228.2% | |
| 3.0% | 0.2% | 0.1% | -3.2% | – | – | – | 0.5% | – | 0.0% | 0.0% | 0.3% | – | |
| -416.8% | -167.0% | -172.1% | -42.7% | -211.0% | -216.0% | -223.0% | -319.1% | -377.6% | -190.3% | -658.3% | -99.6% | -228.4% | |
| -345.0% | -8.9% | -156.4% | -34.6% | -212.5% | -135.2% | -208.0% | -300.9% | -354.5% | -180.2% | -624.2% | -92.6% | -215.1% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 8, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.